Biopharmaceutical News and Research

RSS

ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer.

6 May 2014

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60.

2 May 2014

Otonomy secures $49M in oversubscribed Series D round of financing

Otonomy, Inc., a biopharmaceutical company developing and commercializing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has secured $49 million in an oversubscribed Series D round of financing.

30 Apr 2014

Alkermes reports financial results for first quarter of 2014

Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and enabling us to invest in our advancing late-stage pipeline and prepare for the launch of aripiprazole lauroxil," commented James Frates, Chief Financial Officer of Alkermes.

30 Apr 2014

Scientific data confirms therapeutic potential of Anavex's S1R agonist against Parkinson’s disease

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, other diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research study published in the current issue of peer-reviewed scientific journal Brain.

30 Apr 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences.

28 Apr 2014

Agenus enters into agreement with Merck for development of therapeutic antibodies

Agenus Inc. announced today that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer. Under the terms of the agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the 4-Antibody Retrocyte Display® platform.

28 Apr 2014

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries.

28 Apr 2014

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.

26 Apr 2014

NIH award reflects urgency of overcoming infections that resist drug treatment

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health has selected infectious disease expert David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, to lead a major research effort aimed at developing new forms of antibiotics to regain the upper hand over deadly bacteria that have become resistant to current treatments.

26 Apr 2014

Alimera Sciences inks Loan and Security Agreement with Hercules Technology Growth Capital

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences Limited, has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a term loan in the principal amount of up to $35 million.

25 Apr 2014

NeoGenomics' revenue up 16.1% in first quarter 2014

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2014.

23 Apr 2014

NovaBay introduces new eye care product to help patients with eyelids irritation

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it is introducing a new eye care product, i-Lid Cleanser.

23 Apr 2014

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.

21 Apr 2014

Blog explains why NeutroPhase can play important role in treating 'flesh-eating' infections

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that WoundSource™ has highlighted NovaBay's NeutroPhase wound cleanser in a recent blog posting. The blog explains why NeutroPhase can play an important role in treating life-threatening necrotizing fasciitis, or 'flesh-eating' infections.

21 Apr 2014

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.

From Medtronic 18 Apr 2014

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures.

16 Apr 2014

Epirus Biopharmaceuticals to merge with Zalicus

Zalicus Inc., and Epirus Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.

16 Apr 2014

Wilson Therapeutics closes $40 million Series B financing

Wilson Therapeutics, a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth LLP and MVM Life Science Partners LLP. The company's founding investor, HealthCap, also participated in the round.

16 Apr 2014

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

16 Apr 2014

Biopharmaceutical News and Research

ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Otonomy secures $49M in oversubscribed Series D round of financing

Alkermes reports financial results for first quarter of 2014

Scientific data confirms therapeutic potential of Anavex's S1R agonist against Parkinson’s disease

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Agenus enters into agreement with Merck for development of therapeutic antibodies

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

NIH award reflects urgency of overcoming infections that resist drug treatment

Alimera Sciences inks Loan and Security Agreement with Hercules Technology Growth Capital

NeoGenomics' revenue up 16.1% in first quarter 2014

NovaBay introduces new eye care product to help patients with eyelids irritation

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Blog explains why NeutroPhase can play important role in treating 'flesh-eating' infections

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

Iconic Therapeutics completes $20 million Series B-1 equity financing

Epirus Biopharmaceuticals to merge with Zalicus

Wilson Therapeutics closes $40 million Series B financing

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

How to optimize your cell line development eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News